Study of ASN51 in Adults With Early Alzheimer's Disease

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

The main purpose of this study is to evaluate the safety, tolerability, and effect on biomarkers of disease pathophysiology and pathology, pharmacokinetics (PK), and preliminary effects on measures of clinical efficacy of multiple doses of ASN51 in adult participants with early Alzheimer's disease (AD).

Key facts

Study ID

NCT06677203

Run by

Asceneuron S.A.

People needed

123

Starts

2024-10-16

Expected to finish

2024-11-08

Last updated by the study team

2025-06-29

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• K2 Medical Research — Clermont, Florida, United States
• K2 Medical Research - The Villages — Lady Lake, Florida, United States
• K2 Medical Research — Maitland, Florida, United States
• Alzheimer's Treatment and Research Center — Stuart, Florida, United States
• Alzheimer's Treatment and Research Center — Wellington, Florida, United States
• Columbus Memory Center, LLC — Columbus, Georgia, United States
• Re:Cognition Health — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.